In our patient, the expression of CD117 and p63, as well as the mentioned markers, led to the need to use additional immunohistochemical markers such as anti-GATA3 for breast cancer metastases and anti-DOG1 for digestive cancer, taking into account the clinical context and the aforementioned observations. This evidence concerns the gene ANO1 and breast cancer.